Evidence library

What happens when you stop a GLP-1?

Stopping the drug usually brings much of the weight back, and that is the flip side of an effect that is real while you take it. Here is what the trials show about regain, staying on, and the habits that most consistently keep weight off.

How to read these grades

Evidence strength

Strong evidence (does / reduces / improves)
Moderate evidence (probably / likely)
Early / weak evidence (may / might)

Tested in GLP-1 users?

Tested in GLP-1 users
Not tested in GLP-1 users
Trial underway

Stop the medication and much of the weight comes back

Strong evidence Tested in GLP-1 users

When people stop a GLP-1, weight regain is the rule, not the exception. Trials have seen up to about two-thirds of the lost weight return within roughly a year. The regain is not total, and it does not mean the drugs "do not work"; it is the flip side of a real effect.

What it rests on

STEP-1 extension 1

The follow-up to the main semaglutide obesity trial tracked people after both the drug and the lifestyle support stopped at week 68. They regained about two-thirds of the lost weight over the next year, ending about 5.6% below where they started.

Semaglutide 2.4 mg, drug + support withdrawn
Rubino 2021 (STEP-4) 2

STEP-4 kept everyone on lifestyle counseling but switched half to placebo after a run-in. The placebo group regained (+6.9%) while those continuing the drug kept losing (−7.9%), so the regain tracked stopping the drug, not lapsed effort.

Semaglutide 2.4 mg, drug withdrawn (lifestyle kept)
Aronne 2024 (SURMOUNT-4) 3

SURMOUNT-4 withdrew tirzepatide from half of participants after a lead-in. The withdrawal group regained (+14%) versus continued loss (−5.5%), but still ended net below where they began, so the regain was partial, not a full reversal.

Tirzepatide, drug withdrawn

Regain happens even when you keep up the healthy habits

Moderate evidence Tested in GLP-1 users

Weight regain after stopping is probably not a willpower failure; in the trial that held lifestyle support constant, people regained anyway when only the drug was withdrawn. The drug is doing physiological work that habits alone do not fully replace.

What it rests on

Rubino 2021 (STEP-4) 2

STEP-4 kept everyone on lifestyle counseling but switched half to placebo after a run-in. The placebo group regained (+6.9%) while those continuing the drug kept losing (−7.9%), so the regain tracked stopping the drug, not lapsed effort.

Semaglutide 2.4 mg, drug withdrawn (lifestyle kept)
Mozaffarian 2025 advisory 4

A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

Four-society expert consensus

Staying on the drug keeps the weight off

Strong evidence Tested in GLP-1 users

Continuing a GLP-1 sustains and even extends the weight loss, much like a treatment for a chronic condition where the benefit lasts as long as the treatment does. This is the fair counterweight to regain: stopping brings weight back, staying on holds it off.

What it rests on

Rubino 2021 (STEP-4) 2

STEP-4 kept everyone on lifestyle counseling but switched half to placebo after a run-in. The placebo group regained (+6.9%) while those continuing the drug kept losing (−7.9%), so the regain tracked stopping the drug, not lapsed effort.

Semaglutide 2.4 mg, drug withdrawn (lifestyle kept)
Aronne 2024 (SURMOUNT-4) 3

SURMOUNT-4 withdrew tirzepatide from half of participants after a lead-in. The withdrawal group regained (+14%) versus continued loss (−5.5%), but still ended net below where they began, so the regain was partial, not a full reversal.

Tirzepatide, drug withdrawn

In the real world, most people stop within a year, often over cost

Moderate evidence Tested in GLP-1 users

Outside trials, stopping is common and early: about a third stop by 12 months overall, and roughly half of those taking it for obesity alone, with cost and access among the leading factors. The study measured who stops, not why, so treat the cost link as an association.

What it rests on

Do 2024 5

A study of pharmacy claims for 195,915 US patients tracked how many stopped their GLP-1. About a third stopped by 12 months overall, and roughly half of those taking it for obesity alone, with higher odds when out-of-pocket costs were high. It measured stopping, not the reasons.

195,915 US insurance claims
Mozaffarian 2025 advisory 4

A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

Four-society expert consensus

What actually sustains weight loss: activity, self-monitoring, steady eating

Moderate evidence Not tested in GLP-1 users

The behaviors most consistently linked to keeping weight off are regular physical activity, self-monitoring, and steady everyday eating, and it tends to get easier the longer you sustain it. This comes from weight-control registries, not GLP-1 users, and weight-loss supplements are notably not on the list.

What it rests on

Paixão 2020 6

A systematic review of 52 studies across five national weight-control registries looked at what keeps weight off. Regular physical activity was the most consistent factor, along with self-weighing and steady eating; weight-loss supplements were used by under 20% and were negatively associated in one study.

Weight-control registries, not GLP-1
Mozaffarian 2025 advisory 4

A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

Four-society expert consensus

No trial has tested a structured off-ramp for coming off a GLP-1

Strong evidence Not tested in GLP-1 users

Whether a structured nutrition-and-lifestyle program can blunt the regain after stopping a GLP-1 has never been tested in a controlled trial. The gap itself is a plainly stated fact. Building habits first is reasonable, but no program is yet proven to prevent regain.

What it rests on

Mozaffarian 2025 advisory 4

A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

Four-society expert consensus

What would change this grade

The advisory points to a cost simulation of a staged drug-then-lifestyle program, but that paper is still being sourced and is a projection, not an outcome trial. A controlled off-ramp trial would settle this.

Sources

1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725
2. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414. doi:10.1001/jama.2021.3224
3. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 2024;331(1):38. doi:10.1001/jama.2023.24945
4. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023
5. Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U. GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes. JAMA Netw Open. 2024;7(5):e2413172. doi:10.1001/jamanetworkopen.2024.13172
6. Paixão C, Dias CM, Jorge R, et al. Successful weight loss maintenance: A systematic review of weight control registries. Obesity Reviews. 2020;21(5). doi:10.1111/obr.13003